ArticleThe American journal of tropical medicine and hygiene2025
Mumps Seroprevalence in Vellore, South India: A Community-Based Cross-Sectional Study.
Article in The American journal of tropical medicine and hygiene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mumps vaccine remains excluded from India's National Immunization Schedule (NIS) because of insufficient data on the community-level disease burden, despite mumps being a vaccine-preventable disease. In the present study, biobanked serum samples from an urban population in Vellore, stratified by age (in age groups of 1-5, 6-15, and 16-40 years) and sex, were tested for anti-mumps IgG antibodies using ELISA. The seroprevalence rates of mumps were 26%, 71%, and 84% in the 1- to 5-year, 6- to 15-year, and 16- to 40-year age groups, respectively, indicating a high burden in the community. Women in the 16- to 40-year age group exhibited a higher seroprevalence compared with males, with antibody levels consistently lower in males across both the 6- to 15-year and 16- to 40-year age groups (P <0.05). The present study highlights increasing mumps exposure with age and underscores the urgent need to include the mumps vaccine in the NIS to address the high disease burden and prevent complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.